HHS cancels funding for Moderna to develop vaccines to combat bird flu
The department cited Moderna’s use of the messenger RNA technology, which it said “remains under-tested,” for the cancellation of the funding.
View original article
Contributor: Rachel Roubein, Lena H. Sun
